Triple Therapy Boosts Anaplastic Thyroid Cancer Survival : c

With the neoadjuvant regimen of pembrolizumab added to dabrafenib and trametinib, survival in BRAF-mutated forms of the highly aggressive cancer can go from months to more than 5 years.

Related Keywords

United States , Tampa , Florida , Texas , Washington , Houston , American , Sarah Hamidi , Mariae Cabanillas , Sarimar Agosto Salgado , H Lee Moffitt Cancer Center , Department Of Head , Research Institute , Department Of Endocrine Neoplasia , Md Anderson Cancer Center , American Thyroid Association , University Of Texas Md Anderson Cancer Center , Drug Administration , Endocrine Neoplasia , Hormonal Disorders , Cancer Center , Medscape Medical , Endocrine Oncology , Moffitt Cancer Center , Thyroid Cancer , Thyroid Carcinoma , Ancer Of The Thyroid , Malignant Head And Neck Neoplasm , Thyroid Disorder , Anaplastic Thyroid Carcinoma , Naplastic Carcinoma Of The Thyroid , Otolaryngology , Nt Ears , Nose , Throat , Skin Cancer , Alignant Skin Neoplasm , Toxicology , Cancer , Alignant Neoplasia , Arcinoma , Thyroid , Biologic Therapy , Neoadjuvant , Kbraf , Melanoma , Malignant Melanoma , Braf Inhibitors , B Raf Inhib ,